Rubicon targets Europe for "smallest" embolic filter:
This article was originally published in Clinica
Rubicon Medical plans to begin clinical studies by the first quarter of 2003 to support a European CE-marking application to use its Rubicon embolic filter in patients with saphenous vein grafts, whereby vessel blockages have reappeared following heart bypass. The device, which is claimed to be smaller and easier to insert into blood vessels than rival devices, targets a potential $1bn worldwide market, says Rubicon. The Salt Lake City, Utah firm will also seek US FDA approval for the device following completion of the European studies.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.